一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-121 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置 2018 年公开发行可转换公司债券 募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置2018年公开发行可转换公司债券募集资金进行现金管理的议 案》，同意公司使用额度不超过人民币3.25亿元的2018年公开发行可转换公司债券的暂时闲置 募集资金进行现金管理（包括但不限于购买一年期以内的固定收益型或保本浮动收益型理财产 品、大额存单、定期存款、通知存款、协定存款等），以上额度为在投资期限内任一时点的现 金管理金额(含前述投资的收益进行再投资的相关金额)不超过3.25亿元人民币。在上述额度内， 资金可以滚动使用，在额度范围内授权董事长具体办理实施相关事项。独立董事、保荐机构对 上述议案发表了审查意见。 一、本次进行现金管理基本情况 近日，子公司与上海浦东发展银行股份有限 ...

Group 1 - The core point of the announcement is that shareholder Mr. Ruan Hongxian has repaid a stock pledge financing agreement with Huatai Securities ahead of schedule, releasing 6.2 million shares from pledge [1][2] - As of the announcement date, Mr. Ruan has a total of 148.61529 million shares that remain unpledged, indicating a significant buffer against potential margin calls [3] - The company will continue to monitor Mr. Ruan's stock pledge situation and will announce any changes promptly [3] Group 2 - The company has approved the use of up to RMB 2.5 billion of temporarily idle self-owned funds for cash management, which includes investments in fixed-income products and time deposits [7] - The company has begun to recover funds from cash management products that have reached maturity, indicating active management of its idle funds [7] - Relevant documents related to the cash management activities have been prepared for review [8]

Core Viewpoint - The performance of seven listed chain pharmacies in the third quarter of this year shows a mixed picture, with some achieving growth in both revenue and net profit, while others experienced declines. The overall trend indicates a slowdown in store expansion and a focus on improving quality and efficiency in the industry [1][12]. Revenue and Profit Summary - Dazhenglin reported revenue of 20.068 billion yuan, a year-on-year increase of 1.71%, and a net profit of 1.081 billion yuan, up 25.97% [2][3]. - Yifeng Pharmacy achieved revenue of 17.286 billion yuan, a slight increase of 0.39%, with a net profit of 1.225 billion yuan, growing by 10.27% [2][3]. - Laobaixing's revenue decreased by 1% to 16.07 billion yuan, with a net profit of 529 million yuan, down 16.11%, the largest decline among the seven pharmacies [2][4]. - Yixin Tang's revenue was 13.001 billion yuan, down 4.33%, and net profit was 269 million yuan, down 8.17% [2][4]. - Jianzhijia reported revenue of 6.549 billion yuan, a decrease of 2.8%, and net profit of 101 million yuan, down 0.2% [2][5]. - Shuyupingmin achieved revenue of 7.446 billion yuan, up 5.19%, and net profit of 109 million yuan, a significant increase of 927.37% [2][6]. - Huaren Health, listed in March 2023, reported revenue of 3.892 billion yuan, a growth of 19.06%, and net profit of 157 million yuan, up 45.21% [2][6]. Store Expansion and Market Trends - The rapid expansion of chain pharmacies has slowed, with many companies pausing new store openings. The total number of pharmacies in the country decreased by 0.5% in the third quarter of 2024, marking the first quarterly decline in recent years [7][8]. - Dazhenglin had 16,833 stores by the end of the reporting period, with a significant number of closures [8][10]. - Laobaixing had 15,492 stores, closing 304 and opening 756, while Yifeng Pharmacy had 14,666 stores, closing 440 [9][10]. - Yixin Tang closed more stores than it opened, with 430 closures and only 288 new stores [9][10]. - Shuyupingmin made strategic acquisitions, adding 754 stores in its core market of Shandong, while Huaren Health also expanded its store count through new openings and acquisitions [11][12]. Industry Challenges and Adjustments - The industry is facing multiple pressures, including regulatory changes and increased competition, leading to a decline in profitability for many chain pharmacies. Companies are focusing on closing underperforming stores and improving operational efficiency [12]. - The shift towards online and offline integration is expected to accelerate, with larger listed chains likely to benefit from increased market concentration [12].

Core Insights - The performance of seven listed chain pharmacies in the third quarter of this year shows a mixed picture, with some achieving growth in both revenue and net profit, while others experienced declines [1][3][4]. Revenue and Profit Performance - Dazhenlin reported a revenue of 20.068 billion yuan, a year-on-year increase of 1.71%, and a net profit of 1.081 billion yuan, up 25.97% [2][3]. - Yifeng Pharmacy achieved a revenue of 17.286 billion yuan, a slight increase of 0.39%, and a net profit of 1.225 billion yuan, growing by 10.27% [2][3]. - Laobaixing's revenue decreased by 1% to 16.07 billion yuan, with a net profit of 529 million yuan, down 16.11%, the largest decline among the seven pharmacies [2][4]. - Yixin Tang's revenue was 13.001 billion yuan, down 4.33%, and net profit was 269 million yuan, down 8.17% [2][4]. - Jianzhijia reported a revenue of 6.549 billion yuan, a decrease of 2.8%, and a net profit of 101 million yuan, down 0.2% [2][5]. - Shuyupingmin achieved a revenue of 7.446 billion yuan, up 5.19%, and a net profit of 109 million yuan, a significant increase of 927.37% [2][6]. - Huaren Health, listed in March 2023, reported a revenue of 3.892 billion yuan, a growth of 19.06%, and a net profit of 157 million yuan, up 45.21% [2][6]. Store Expansion Trends - The rapid expansion of chain pharmacies has slowed down, with many companies pausing new store openings and focusing on improving efficiency [1][7]. - The total number of pharmacies in the country decreased by 0.5% in the third quarter of 2024, marking the first quarterly decline in recent years [7]. - Dazhenlin had 16,833 stores by the end of the reporting period, with a net increase of only 152 self-built stores and no new acquisitions [8][12]. - Laobaixing had 15,492 stores, closing 304 and opening 756, with a significant portion being franchise stores [9][12]. - Yifeng Pharmacy had 14,666 stores, closing 440 and opening 422, including franchises [10][12]. - Yixin Tang closed 430 stores while opening only 288, indicating a contraction in its store network [11][12]. - Shuyupingmin, however, expanded through acquisitions, adding 754 stores in the Shandong region [13][14]. Industry Challenges and Adjustments - The industry is facing multiple pressures, including regulatory changes and increased competition, leading to a decline in profitability for many pharmacies [15]. - Companies are focusing on closing underperforming stores and improving operational efficiency as part of their strategic adjustments [15].

每经头条（nbdtoutiao）——展望"十五五"|专访财科院院长杨志勇：遏制地方政府新增隐性债务，债务 信息要透明，尽可能降低利息成本 （记者 曾健辉） 每经AI快讯，一心堂（SZ 002727，收盘价：14.17元）11月14日晚间发布公告称，截至本公告日，阮鸿 献累计质押股数为3363万股，合计占其所持股份比例为18.45%。 2025年1至6月份，一心堂的营业收入构成为：零售占比73.14%，批发占比23.68%，其他业务占比 3.17%。 截至发稿，一心堂市值为83亿元。 ...

Core Insights - The pharmaceutical commercial sector experienced a rise of 1.05% on November 14, with significant gains led by the stock of Jiyu Pingmin, which surged by 20.03% [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jiyu Pingmin (301017) closed at 16.66 with a gain of 20.03%, trading volume of 141,800 shares and a transaction value of 227 million [1] - Renmin Tongtai (600829) and Kaikai Industry (600272) also saw notable increases of 10.04% and 10.03%, respectively [1] - The pharmaceutical sector's stocks showed a mixed performance, with some stocks like Jianfa Zhixin (301584) and Runda Medical (603108) declining by 3.33% and 1.59% respectively [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million from institutional investors, while retail investors contributed a net inflow of 590 million [2][3] - The main stocks experiencing significant net inflows from retail investors included Jiyu Pingmin and Kaikai Industry, while institutional investors showed a preference for stocks like Kaikai Industry [3]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-119 号 一心堂药业集团股份有限公司 关于公司股东阮鸿献先生部分股票质押融资 提前还款解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）近日接到公司股东阮鸿献先生通知， 获悉阮鸿献先生与华泰证券股份有限公司（以下简称"华泰证券"）达成协议，将 2024 年 6 月 6 日向华泰证券申请办理的股票质押融资业务进行提前还款并解除股票质押，具体事项如下： 一、股东股份质押情况 1、股份质押解除情况 | 股东名称 | 是否为控股 股东或第一 | 本次解除质 | 占其所持 | 占公司 | | | 质权人/申 | 备注 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押股份数量 | | 总股本 | 起始日 | 解除日期 | | | | | 大股东及其 | （万股） | 股份比例 | 比例 | | | 请人等 | | | | 一致行动人 | | | | ...

股票代码：002727 股票简称：一心堂 公告编号：2025-120 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理到期收回的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心为民 全心服务 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、现金管理到期收回情况 根据 2024 年年度股东会决议，公司与相关银行签署合同，使用部分暂时闲置自有资金进 行现金管理，现部分产品到期收回，基本情况如下： | 签约银行名称 | 产品名称 | 认购金额 （万元 ...

2.本次股东会不涉及变更前次股东会决议。 登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：002727 股票简称：一心堂 公告编号：2025-117号 一心堂药业集团股份有限公司 2025年度第三次临时股东会 暨中小投资者表决结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1.本次股东会没有增加、否决或变更提案。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议时间：2025年11月13日（星期四）下午14点。 （2）网络投票时间：2025年11月13日。其中，通过深圳证券交易所交易系统进行网络投票的具体时间 为2025年11月13日9:15一9:25，9:30一11:30和13:00一15:00；通过深圳证券交易所互联网投票系统进行 网络投票的具体时间为2025年11月13日上午9:15至下午15:00的任意时间。 2.召开地点：一心堂药业集团股份有限公司会议室 3.召开方式：现场投票及网络投票 4.召集人：本公司董事会 5.主持人：董事长阮鸿献先生。 6.会议通知于2025年10月28日刊登在《证 ...

证券日报网讯11月13日晚间，一心堂（002727）发布公告称，选举郭春丽女士为第七届董事会职工代表 董事。 ...